Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
Deals
Features
News
Region
Sectors
Size

$100m-$499m

Dexterity extracts $140m from investors
The warehouse robot developer’s latest round has pushed its total funding past the $200m mark since being founded out of Stanford in 2017.
Lilac mines investors for $150m close
The Engine was among the investors that helped the lithium mining process developer raise a series B round first announced last month.
Lilac coats series B in $150m
The Engine has reinvested in Lilac Solutions, a lithium extraction technology developer building on research at Northwestern University.
EnerVenue electrifies $100m series A
Stanford University has backed a round that will help the nickel-hydrogen battery developer finance construction of a Gigafactory.
AgBiome cultivates $116m series D
UNC Chapel Hill’s agricultural technology developer AgBiome has increased its overall funding to $230m following the series D round.
Lexeo Therapeutics bags $100m
Cornell spinout Lexeo Therapeutics has added $100m to its coffers thanks to a series B round co-led by D1 Capital Partners and Eventide Asset Management.
Spiber threads in $312m
Keio’s synthetic silk producer increased its valuation to over $1.2bn in a round led by Carlyle Japan Partners.
XSky stores $110m in series E
The Tsinghua-backed data storage company has secured backing from corporates Legend Holdings and Hundsun to further develop its technology.

Other News

Offchain blocks in $120m of funding
The Ethereum scaling technology developer raised two rounds this year, having spun out of Princeton in 2018.
Form Energy finalises $240m series D
MIT’s energy storage technology producer had secured an initial $200m tranche last month, with existing backer The Engine contributing to the round.
Apeel appears with $250m series E
The UC Santa Barbara-launched food preservation technology developer’s latest round valued it at $2bn.
GentiBio jumps to $157m series A
Matrix Capital Management led the immunology drug developer's series A round, which will support the journey of a type 1 diabetes drug candidate towards the clinic.
Tulip nabs $100m in series C round
The no-code platform developer, spun out of MIT's Media Lab, will use the cash to boost international growth and accelerate the development of new product features.
Ambri absorbs $144m
The renewable energy battery developer, an MIT spinout, raised funding that will be used to expand its manufacturing capabilities.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg

Login